TTR Amyloidosis Phase IIa results will be presented by Dr. Josep Gàmez at AAN 2016 Annual Meeting to be held in Vancouver (Canada) from 15th to 21th of April. This Clinical Trial has been performed by SOM Biotech and VHIR (Vall d'Hebron Hospital Institute of Research). Further information about the meeting at AAN 2016 Annual…

The article ‘Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity’ has recently been published on Nature Communications. SOM0226 (tolcapone) is a strong candidate for therapeutic intervention in the TTR Amyloidosis variants, including those affecting the central nervous system, for which no small-molecule therapy exists. Several institutions have taken part on this research as…

SOM Biotech is a repositioning clinical-stage biopharmaceutical company focused on Rare Diseases. Why repositioning and orphan? See this article to get the answer. Chinese Version English Version 

SOM Biotech has launched a crowdfunding campaign

SOM Biotech will attend next JP Morgan Healthcare Conference 2016. This event will take place in San Francisco, CA from January 11-14, 2016.  If you are interested in meeting SOM Biotech delegates and knowing more about SOM's current programs, send an email to [email protected] to arrange a meeting. In addition, SOM Biotech delegates will also be attending the 8th…

SOM Biotech and the Vall d'Hebron Research Institute (VHIR) have completed a Phase IIa Clinical Study with compound SOM0226,